Ceribell Inc (CBLL) Stock Forecast & Price Target

CeriBell is viewed positively because it has delivered sustained execution since its IPO, beating sales expectations, raising revenue guidance each quarter, and expanding its addressable market from $2B to more than $3.5B through pediatric, neonate, and delirium approvals. Its core thesis is strengthened by a differentiated point-of-care EEG platform with AI-driven software, gross margin of 92.3% in Q2, 712 active hospital accounts, and less than 4% penetration in the core seizure market, leaving substantial room for adoption. The outlook is further supported by a 2026 revenue guide of $114M to $117M, new FDA-cleared algorithm upgrades, and a next-gen hardware platform that could compound growth across multiple indications while supporting cash-flow breakeven.

CeriBell is viewed negatively because its core commercial opportunity may be less defensible than it appears, with current delirium monitoring still dominated by subjective, intermittent nurse-driven tools like CAM-ICU and ICDSC, while competing products such as DeltaScan and broader EEG alternatives could limit adoption. Although survey data point to ~30% CAGR growth in Ceribell EEG use between 2025 and 2028, the outlook is offset by meaningful execution and margin risks, including subpar financial results, reimbursement pressure, launch delays, competition, and potential tariff-related gross margin compression from China sourcing. Legal and regulatory catalysts also look less decisive than they seem, since the USITC case’s commercial importance is reduced by BrainWatch’s limited traction, even as Ceribell still faces uncertainty around patent outcomes, deferred legal fees of $2.9M, and risks tied to R&D and expanding indications like delirium and stroke.